These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32209344)

  • 1. Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice.
    Suresh R; Yu HJ; Thoveson A; Swisher J; Apolinario M; Zhou B; Shah AR; Fish RH; Wykoff CC
    Am J Ophthalmol; 2020 Jul; 215():66-71. PubMed ID: 32209344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Lost to Follow-Up in Patients Being Treated for Proliferative Diabetic Retinopathy.
    Green M; Tien T; Ness S
    Am J Ophthalmol; 2020 Aug; 216():18-27. PubMed ID: 32243878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
    Obeid A; Gao X; Ali FS; Talcott KE; Aderman CM; Hyman L; Ho AC; Hsu J
    Ophthalmology; 2018 Sep; 125(9):1386-1392. PubMed ID: 29606377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage.
    Angermann R; Rauchegger T; Nowosielski Y; Casazza M; Bilgeri A; Ulmer H; Zehetner C
    Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2119-2125. PubMed ID: 31286206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Obeid A; Gao X; Ali FS; Aderman CM; Shahlaee A; Adam MK; Kasi SK; Hyman L; Ho AC; Hsu J
    JAMA Ophthalmol; 2018 Nov; 136(11):1251-1259. PubMed ID: 30352121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy.
    Tsui JC; Yu Y; VanderBeek BL
    JAMA Ophthalmol; 2023 Jan; 141(1):40-46. PubMed ID: 36454552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss to Follow-up After Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Patients with Diabetic Macular Edema.
    Gao X; Obeid A; Aderman CM; Talcott KE; Ali FS; Adam MK; Rovner BW; Hyman L; Ho AC; Hsu J
    Ophthalmol Retina; 2019 Mar; 3(3):230-236. PubMed ID: 31014699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss to Follow-Up in Patients With Retinal Vein Occlusion Undergoing Intravitreal Anti-VEGF Injections.
    Gao X; Obeid A; Adam MK; Hyman L; Ho AC; Hsu J
    Ophthalmic Surg Lasers Imaging Retina; 2019 Mar; 50(3):159-166. PubMed ID: 30893449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabetes.
    Vail D; Callaway NF; Ludwig CA; Saroj N; Moshfeghi DM
    Am J Ophthalmol; 2019 Nov; 207():378-384. PubMed ID: 31194953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
    Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial.
    Figueira J; Silva R; Henriques J; Caldeira Rosa P; Laíns I; Melo P; Gonçalves Nunes S; Cunha-Vaz J
    Ophthalmologica; 2016; 235(1):34-41. PubMed ID: 26630400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
    Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR;
    Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
    Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
    Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.